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Over the past decades, an emerging role of phosphatases in the pathogenesis of hemato-
logic malignancies and solid tumors has been established. The tumor-suppressor protein
phosphatase 2A (PP2A) belongs to the serine–threonine phosphatases family and accounts
for the majority of serine–threonine phosphatase activity in eukaryotic cells. Numerous
studies have shown that inhibition of PP2A expression and/or function may contribute to
leukemogenesis in several hematological malignancies. Likewise, overexpression or aber-
rant expression of physiologic PP2A inhibitory molecules (e.g., SET and its associated
SETBP1 and CIP2A) may turn off PP2A function and participate to leukemic progression.
The discovery of PP2A as tumor suppressor has prompted the evaluation of the safety
and the efficacy of new compounds, which can restore PP2A activity in leukemic cells.
Although further studies are needed to better understand how PP2A acts in the intricate
phosphatases/kinases cancer network, the results reviewed herein strongly support the
development on new PP2A-activating drugs and the immediate introduction of those avail-
able into clinical protocols for leukemia patients refractory or resistant to current available
therapies.
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INTRODUCTION
The phosphorylation status of proteins is crucial in regulating
their functions and properties. In normal cells, kinases and phos-
phatases participate to phosphorylation processes (1). By mod-
ulating the phosphorylated load, they control the on–off switch
of target proteins. The balance between kinase and phosphatase
activities is critical in many hematological malignancies. Although
numerous studies highlighted the role of kinases in malignant
transformation, much less is known about the contribution of
specific phosphatases to cancer development.
Oncogenic kinases and tumor-suppressor phosphatases main-
tain the cell homeostasis by exerting their activities on cell growth,
survival, and differentiation. Thus, aberrant oncogene expres-
sion and loss of tumor-suppressor gene function affect cell cycle,
apoptosis, and DNA damage repair machineries. ABL1 is a well-
characterized kinase that has been involved in leukemic transfor-
mation (2). The break cluster region (BCR)–ABL1 oncoprotein is a
tyrosine-kinase that constitutively activates downstream signaling
thereby inducing cell proliferation, survival, and clonal expan-
sion in chronic myeloid leukemia (CML) and a cohort of acute
lymphoblastic leukemia (ALL) patients. In addition to the tumor-
suppressors TP53, RB1, and ATM, usually lost in several leukemias,
inhibition of specific phosphatases expression or loss of their func-
tion has been recently detected in many cancers (3). Interestingly,
there is increasing evidence that unrestrained oncogene kinase
activity is not sufficient to transform cells if a concurrent inhibi-
tion of the antagonizing tumor-suppressor phosphatases does not
occur (4).
The introduction of tyrosine-kinase inhibitors [TKIs; e.g., ima-
tinib (IM)] has dramatically changed the clinical outcome of
patients with hematological malignancies (5). However, the occur-
rence of mutations at the active kinase site or additional chromo-
somal/molecular abnormalities resulting in drug resistance and,
possibly, disease progression (6) indicate that new strategies are
needed to prolong survival of leukemia patients resistant or refrac-
tory to current chemo and TKI-based therapies. Although the
rescue of tumor-suppressor function seems to be an intriguing
challenge in cancer treatment, few molecules have been proven to
target specifically tumor-suppressors.
Protein phosphatase 2A (PP2A) refers to a family of serine–
threonine phosphatases that accounts for the majority of serine–
threonine phosphatase activity in eukaryotic cells (7). In the last
decade, an emerging role of PP2A in the onset and progression
of solid tumors and hematological malignancies has been estab-
lished (8, 9). These findings led to the discovery and development
of a new family of compounds, the PP2A-activating drugs (PADs)
that are capable of restoring PP2A phosphatases activity of most
of them through interference between PP2A and its inhibitor
SET/I2PP2A (8, 10). Pre-clinical studies proved the efficacy and
no-toxicity of PADs in several ex vivo and in animal studies (8),
indicating that PP2A reactivation in combination with kinase inhi-
bition or chemotherapy represents a feasible and effective strategy
for the treatment of hematological malignancies.
PP2A IN NORMAL CELLS
PP2A STRUCTURE AND REGULATION
The PP2A core enzyme consists of a 36 kDa catalytic C sub-
unit (PP2AC) and a 65 kDa structural A subunit (PP2AA). In
mammals, two isoforms (α and β) are encoded for each subunit
(Aα, Aβ, Cα, and Cβ) (11). The structure of the PP2A complex is
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enriched with a regulatory B subunit. Four families of the B sub-
unit, with a molecular weight ranging from 50 to 130 kDa, have
been identified: PP2AB (B55 or PR55), PP2AB′ (B56 or PR61),
PP2AB′′ (B72 or PR72; B130 or PR130; PR48; and G5PR) PP2AB-
(PR93 and PR110). By assembling differently the A, B, and C sub-
unit isoforms, more than 75 distinct PP2A holoenzymes could be
built up (12).
The A and C subunits are evolutionary conserved and ubiq-
uitously expressed. These two subunits form a catalytic complex
(PP2A/AC) that can interact with the regulatory B subunits or
certain viral antigens (e.g., polyoma small T and middle T anti-
gens, and SV40 small tumor antigen) to affect activity and deter-
mine PP2A substrate and tissue specificity (12, 13). Moreover,
the B subunit may vary depending on stage-development (14,
15) and it can recruit PPA2/AC to a selective subcellular com-
partment (cytoplasm or nucleus) driving it to a specific substrate
target (1).
The ability of PP2A to regulate different cellular activities
depending on its structure and composition renders this enzyme
a suitable target for new therapeutic compounds as improving the
drug affinity for each isoform might entail high tissue specificity
and better safety profile.
PP2A PATHWAYS
Protein phosphatase 2A is involved in a consistent number of phys-
iological processes in adult and embryonic cells (Figure 1). For
example, the transcription factor β-catenin, which is the major
effector in the Wnt signaling pathway both in cancer and embry-
onic development (12, 16) undergoes PP2A-dependent regulation.
PP2A also plays an essential role in cell division and apoptosis
depending on the specific isoform constituting the PP2A holoen-
zyme (17, 18). Indeed, PP2A is required to maintain G1/S cyclin
levels by modulating their phosphorylation status, a necessary
event to properly transit through the cell cycle (19).
FIGURE 1 | PP2A networks. PP2A is involved in various cellular signaling
including MAPK/ERK, PI3K/AKT, Jak2, and CDK. Thus, the effects of PP2A
down-regulation could potentially affect multiple pathways resulting in
alteration of apoptosis, cell growth, proliferation, and differentiation in adult
cells.
Notably, PP2A loss-of-function results in inhibition of apop-
tosis. This mostly depends on interference with two major mito-
genic/survival pathways: the MAPK/ERK and the PI3K/AKT cas-
cades. In normal cells, specific PP2A complexes desphosphorylate
and inactivate MEK and ERK1 kinases thereby keeping the activity
of many signal transducers, apoptosis regulators, and transcription
factors (e.g., STAT5 and 3; c-Myc) tightly regulated. PIM1 kinase
protein is a target of PP2A and once it is dephosphorylated by
PP2A, it is degraded by the proteasome machinery (20). Further-
more, PIM1 represses the pro-apoptotic molecule BAD through
its phosphorylation at Ser112 gatekeeper site (21). Likewise, PP2A
suppresses PI3K/AKT-generated signals mostly by direct AKT
dephosphorylation but also through activation of GSK-3b or inhi-
bition of cytokine-generated signals, which lead to Akt-activation
(22, 23).
In addition to the MAPK/ERK and PI3K/AKT cascades, PP2A
function is strictly related with the Janus kinase 2 (Jak2) tyrosine
kinase (24, 25). In IL-3-stimulated myeloid progenitor cells, the
interaction between Jak2 and PP2A transiently increases and Jak2
becomes activated and PP2Ac activity suppressed by phosphory-
lation on Y307 (26). In primary myeloid stem and progenitors
cells, reactivation of PP2A also induces Jak2 inactivation thus
resulting in shut-down of mitogenic/survival cytokine-generated
signals (27).
PP2A INHIBITORS
Physiologic PP2A inhibitors seem to be involved in the
mechanisms of progression and aggressiveness of hema-
tological malignancies. ANP32A (I1PP2A), SET (I2PP2A),
CIP2A, SETBP1A, type 2A-interacting protein (TIP), and
ENSA are well-characterized cellular PP2A inhibitory molecules
(Table 1).
Table 1 | PP2A inhibitors in hematological malignancies.
PP2A inhibitors Pattern of expression Hematological
malignancies
SET (I2PP2A) Overexpression/gain of
function
CML, CLL, NHL cell line,
Jak2V617MPN, AML
SETBP1 Mutations
Overexpression/gain of
function
aCML, sAML, CMML, CNL,
unclassified MDS/MPN
CIP2A Overexpression CML
ANP32A (I1PP2A) Overexpression K562 cell line
TIP Unknown Unknown
ENSA Unknown Unknown
CML, chronic myeloid leukemia; CLL, chronic lymphocytic leukemia; NHL, non-
Hodgkin lymphoma; Jak2 V617MPN, Jak2V617F positive myeloproliferative neopla-
sia; AML, acute myeloid leukemia; aCML, atypical chronic myeloid leukemia;
sAML, secondary acute myeloid leukemia; CMML, chronic myelomonocytic
leukemia; CNL, chronic neutrophilic leukemia; unclassified MDS/MPN, unclas-
sified myelodisplastic/myeloproliferative neoplasia.
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SET and SET binding protein (SETBP1) act synergistically
and permit the formation of the SETBP1/SET/PP2A complex,
which inhibits PP2A phosphatase activity (28). SET (or I2PP2A)
is a potent endogenous inhibitor of the tumor-suppressor PP2A
(8) as PP2A acts as a negative regulator of several survival and
proliferation pathways that are aberrantly activated in hematolog-
ical malignancies (8). In addition, it has been reported that SET
inhibits the DNase activity of the tumor-suppressor NM23-H1
and that the cleavage of SET by Granzyme A during the cytotoxic
T lymphocyte-induced apoptosis releases NM23-H1 from inhibi-
tion and triggers NM23-H1 to translocate into the nucleus, where
it cleaves the DNA (29, 30).
SETBP1
SETBP1 localizes on chromosome 18q21.1 and codes for a nuclear
protein of 170-kDa that specifically interacts with SET form-
ing a heterodimer (31). SETBP1 germline mutations have been
described in Schinzel–Giedion syndrome, a rare congenital disor-
der characterized by aberrant bone formation (32) and predispo-
sition to myeloid malignancies. SETBP1 overexpression protects
SET from protease cleavage, increasing the amount of full-length
SET protein and leading to the formation of the SETBP1–SET–
PP2A complex that results in PP2A inhibition (28). Interestingly,
not only SETBP1 overexpression but also SETBP1 mutations have
been associated with hematological disorders (28, 33, 34). Cells
expressing SETBP1 Gly870Ser variant showed higher level of
SETBP1 and SET proteins, and significantly reduced PP2A activity
indicating that SETBP1 mutations contribute to SET stabilization
and PP2A inhibition (34).
An additional PP2A inhibitor is the cancerous inhibitor of PP2A,
e.g., CIP2A, which normally prevents PP2A-mediated dephos-
phorylation of c-Myc at serine 62. pS62-Myc is more stable than
its dephosphorylated counterpart, and CIP2A therefore prevents
c-Myc degradation (35). Moreover, impaired p53 activity was
demonstrated to increase CIP2A expression trough E2F1, which in
turn, by inhibiting PP2A activity, increases stabilizing E2F1 (36).
Whereas in vivo data have confirmed the involvement of SET,
SETBP1, and CIP2A proteins in leukemic transformation process,
so far we could not rule out the contribution to the develop-
ment of hematological malignancies of other molecules that have
been proven to inhibit PP2A including TIP, ANP32A, and ENSA.
Recently, one study has reported that knock-down of the NM23-
H1 factor in CML K562 cell line decreased proliferation and
altered the expression of ANP32A, a potent and selective PP2A
inhibitor (37).
Although variations exist between increased levels of PP2A
inhibitors and adverse clinical outcome in different hematologic
malignancies, pharmacologic suppression of PP2A inhibitors rep-
resents an effective strategy to induce apoptosis of leukemic cells
and/or sensitize resistant cells to TKIs (25, 27, 38–40). Thus, PP2A
reactivation should be taken as a possible therapeutic approach.
PP2A AND HEMATOLOGICAL MALIGNANCIES
CHRONIC MYELOID LEUKEMIA AND MYELOPROLIFERATIVE DISORDERS
Chronic myeloid leukemia
Chronic myeloid leukemia is a myeloproliferative disorder arising
from the transformation of the hematopoietic stem cell (HSC)
and characterized by exuberant cell expansion and altered dif-
ferentiation of myeloid precursors. The molecular hallmark of
CML is the Philadelphia chromosome (Ph) that derives from the
translocation t(9;22) and causes the juxtaposition of the ABL1
kinase gene with the break cluster region gene (BCR) (2). The
BCR–ABL1 fusion oncoprotein is a constitutively active tyrosine
kinase that confers growth factor-independent proliferation and
enhanced survival to the hematopoietic progenitors harboring this
abnormality. Although TKIs control the disease in vast major-
ity of patients, a small proportion of patients with CML will
eventually lose response to TKIs treatment and progress to blast
crisis (BC) (41). The occurrence of mutations at the active site
of BCR–ABL1 may at least in part explain the overcoming resis-
tance in patients treated with TKIs (42). Moreover, the persistence
of quiescent CML HSCs might contribute to disease progression
because TKIs seem to not affect leukemic stem cell prolifera-
tion and survival (43). In CML cells, PP2A is a key target in
BCR–ABL1 downstream signaling and, in fact, the BCR–ABL1
oncoprotein prevents PP2A auto-dephosphorylation at tyrosine
307 (44, 45) thereby keeping PP2A in its inactive status. By tar-
geting BCR/ABL1, TKIs inhibit ABL kinase activity and restore
PP2A function. Interestingly, in IM-resistant CML cells, the sphin-
gosine kinase-1 (SK-1)/sphingosine 1-phosphate (S1P) activation
enhances BCR–ABL1 stability through S1P receptor 2 (S1P2) sig-
naling, which prevents BCR–ABL1 dephosphorylation and degra-
dation through inhibition of PP2A (45). Molecular and pharmaco-
logical interference with SK-1/S1P2 may restore PP2A-dependent
dephosphorylation and enhance IM- or nilotinib-induced growth
inhibition in primary CD34+ CML progenitors and BCR–ABL1+
cell lines.
Recently, it has been shown that persistence of leukemic HSCs
in bone marrow of patients with CML requires the inhibition of the
PP2A and BCR–ABL1 expression but not its activity (27). In com-
parison with HSCs from healthy individuals, PP2A activity was
remarkable suppressed in HSCs from patients with CML (27). This
result is apparently in contrast with the low BCR–ABL1 tyrosine-
kinase activity found in the Ph+ HSC-enriched cell fractions,
which would have expected to be associated with PP2A restoration.
However, BCR–ABL1 expression is needed for the recruitment and
activation of Jak2 that, in turn, triggers SET-dependent PP2A inhi-
bition and activation of β-catenin-mediated self-renewal/survival
signals (27). The consistent difference in PP2A activity in nor-
mal and leukemic HSCs implies that restoration of PP2A activity
would allow the selective targeting of leukemic HSCs without
compromising the normal counterpart (Figure 2).
An additional finding is that in CML stem cells not only
PP2A but also PP2A inhibitory molecules might be aberrantly
expressed and might contribute to low PP2A activity. SET was the
first PP2A inhibitory molecule to have been found up-regulated
in CML (CP and BC) and Ph+ B-ALL CD34+ progenitors
through a BCR–ABL1 dose- and kinase-dependent manner (38).
In CD34+ primary cells from patients with CML-BC and in
BCR–ABL1+ cell lines, SET expression is enhanced by BCR/ABL
and increases during CML disease progression. In fact, SET pro-
tein levels correlate with BCR/ABL activity and are higher in
CML-BC CD34+ than CML-CP CD34+ cells and in CML-CP
CD34+ cells than in CD34+ cells from healthy donors (44).
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FIGURE 2 | PP2A in CML cells. In CML cells, the BCR–ABL1 and the PP2A
pathways are strictly connected. PP2A induces
dephosphorylation/inactivation of BCR–ABL1 and Jak2 tyrosine kinases.
Conversely, BCR–ABL1 induces SET and CIP2A expression thus increasing
the inhibition on PP2A. Jak2 also down-regulates PP2A through SET.
SET-mediated PP2A inactivation is essential for survival/self-
renewal of quiescent CML HSCs and maintenance of an active
Jak2-β-catenin pathway and that PP2A is suppressed in CML
HSCs in a BCR/ABL kinase-independent, Jak2-dependent manner
(27). In BCR/ABL transformed cells, the levels of PP2A struc-
tural subunit PR65/A were found to correlate with increased levels
of PP2Ac phosphorylation on tyrosine 307 which, as reported,
inhibits PP2A activity (44). Accordingly, PP2ATyr307 levels are
markedly reduced upon SET down regulation by means of short-
hairpin RNA (shRNA) or IM treatment (44). The restoration of
PP2A phosphatase activity induces the SHP-1-dependent BCR–
ABL1 dephosphorylation/inactivation and triggers BCR–ABL1
proteasome degradation (44).
Likewise, CIP2A have been found overexpressed in hemato-
logical malignancies and in solid tumors, and to be associated
with high proliferation rate and poor prognosis (46, 47). In a
retrospective study, Lucas et al. have shown that high CIP2A pro-
tein levels are elevated at diagnosis in mononuclear cells (MNCs)
and CD34+ cells from patients with CML who progressed into
BC compared to patients who achieved a complete cytogenetic
response (CCyR) or who had not progressed (48). Interestingly, in
patients who progressed into CML-BC, the CIP2A levels were sus-
tained despite IM treatment and low Sokal score. The inhibition
of CIP2A resulted in a reduction of inactivated phosphorylated
PP2ATyr307 fraction and BCR/ABL1 kinase activity. The knock-
down of CIP2A led to a consistent drop of SET and Jak2 protein
levels, suggesting the existence of an interplay between the PP2A
complexes, their physiologic inhibitors (e.g., SET and CIP2A), and
the BCR–ABL1/JAK2 signalosome (48).
Protein phosphatase 2A is also inactivated in polycythemia
vera (PV), essential thrombocytosis (ET), and primary myelofibrosis
(PMF) and other myeloproliferative disorders (MPDs) character-
ized by the expression of the transforming Jak2V617F oncogene
(25). Consistent with significant reduction of PP2A activity in
CD34+ progenitors from patients with Jak2V617F positive ET, PV,
and MFI, treatment with Jak inhibitors may rescue PP2A activity
through SET silencing (25).
Taken together, these data indicate that the balance among
PP2A, SET, and CIP2A may play a crucial role not only for main-
tenance of CML progenitors both in chronic and blastic phase
but also for the population of leukemic stem cells showing innate
resistance to TKI. This observation has strong critical clinical
implications as drugs that are able to rescue PP2A activity could
potentially eradicate the leukemic HSCs reservoir or be effective
in patients who progress to BC that so far define a clinical stage
characterized by treatment refractoriness and poor prognosis.
MYELODYSPLASTIC SYNDROME AND
MYELODYSPLASTIC/MYELOPROLIFERATIVE NEOPLASMS
In other myeloproliferative malignancies, inhibition of PP2A is
achieved by SET stabilization through its interaction with SETBP1
(31). Recently, by exome sequencing technology, SETBP1 muta-
tions were found to recur frequently in patients with atypi-
cal chronic myeloid leukemia (aCML), a disorder with overlap-
ping clinical features with CML but without the typical Ph1
translocation (34). Out of 644 patient samples with different
myeloid and lymphoid malignancies and 344 cell hematopoietic
and non-hematopoietic lines, the pGly870Ser SETBP1 mutation
occurred in 24% of patients with aCML, and in 25, 10, and 4%
of patients with chronic neutrophilic leukemia (CNL), unclassi-
fied MDS/MPN disorders, and chronic myelomonocytic leukemia
(CMML), respectively. Ectopic SETBP1 Gly870Ser expression in
TF1 enhanced cell proliferation, which likely resulted from sup-
pression of SETBP1 ubiquitination/degradation that, in turn, led
to SET stabilization and PP2A inhibition (34). In primary aCML
cells as well as in cells overexpressing the mutated SETBP1,SETBP1
levels correlated with increased expression of Lyn and PTGS2 (two
known targets of PP2A) and induction of the TGF-β pathway.
Interestingly, aCML patients with SETBP1 mutations had a worse
prognosis than those with wild-type SETBP1 (34).
Similar to what was found in aCML, a different group identified
recurrent somatic mutations in SETBP1 by whole-exome sequenc-
ing of individuals with various myeloid malignancies (49). The
mutations (pAsp868Asn, pGly870Ser, pIle871Thr, pSer869Asn,
and pAsp880Asn or pAsp880Glu) in this cohort of patients corre-
sponded with the recurrent de novo germline mutations respon-
sible of Schinzel–Giedion syndrome and were detected in 15%
of CMML cases and 17% of secondary acute leukemia (sAML).
Mutant cases were associated with advanced age, poor cytoge-
netic abnormalities, and shorter survival. However, in CMML
subgroup, SETBP1 retained its prognostic value in association
with CBL mutations. Furthermore, the sequential analysis of ser-
ial samples at multiple time points of the disease course, in two
different series of patients with myeloid malignancies, showed
that SETBP1 mutations were absent at the time of initial pre-
sentation while increasing in allele frequencies by time (49, 50).
These observations suggest that SETBP1 mutations are acquired
during leukemic evolution contributing to leukemic progression
rather than leukemic transformation. Transduction with mutant
SETBP1 led to the immortalization of mouse myeloid precursors
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that acquired enhanced proliferative capacity and tyrosine phos-
phorylation of PP2A. In addition, a significantly higher HOXA9
and HOXA10 expression levels were observed in SETBP1-mutant
leukemias in comparison with wild-type cases without SETBP1
overexpression (49). Overall, SETBP1 mutations predict poor out-
come irrespective of age, sex, International Prognostic Scoring
System (IPSS), and unfavorable cytogenetic risk (49, 50). How-
ever, the adverse prognostic value of SETBP1 mutations was not
confirmed in two cohorts of patients with aCML and CMML,
probably due to the fact that the median follow-up was relatively
short (33).
Furthermore, SETBP1-mutant cases have been associated with
higher white blood cell counts, high grade thrombocytopenia,
and anemia than wild-type cases (33), with poor risk cytoge-
netic abnormalities like monosomy 7/del7q (33, 49, 50) and
isochromosome i(17) (33, 50). Interestingly, in patients with
i(17)(q10), the TP53 and SETBP1 mutations are mutually exclu-
sive; likewise, SETBP1 mutations rarely occur in cases harboring
Jak2V617F, MPLW515, Jak2 exon 12, and TET2 mutations (33). Con-
versely, ASXL1 and CBL mutations correlate significantly with the
occurrence of SETBP1 mutations (33, 34, 49, 50).
Although further are warranted, SETBP1 mutations seem to
define a subgroup of patients with myeloid disorders characterized
by specific clinical features and worse prognosis.
ACUTE MYELOID LEUKEMIA
An increasing number of studies have shown that the PP2A path-
way is also affected not only in CML but also in other myeloid
malignancies. Over the past few years, large-scale genomic studies
have unveiled the presence of novel genetic aberrations in patients
with acute myeloid leukemia (AML). C-KIT is a type-3 tyrosine-
kinase receptor activating multiple proliferation, differentiation,
and survival signals in stem cells (51). Activating c-KIT mutations
have been differently associated with higher relapse rate, shorter
survival, and TKIs resistance (52). Interestingly, PP2A struc-
tural and regulatory subunits were found significantly reduced
in myeloid cells expressing activated c-KIT mutants, meaning
that PP2A is a crucial mediator of c-KIT leukemogenesis (40).
Accordingly, the overexpression of PP2A-Aα in D816V c-KIT cells
induced apoptosis and inhibited proliferation (40), suggesting
that the restoration of PP2A activity could represent an effective
strategy to overcome drug resistance in c-KIT+ AML.
Cristobal et al. described a novel translocation t(12;18)(p13;q12)
involving ETV6 in a patient with AML. The translocation resulted
in overexpression of SETBP1 (18q12), located close to the break-
point. They demonstrated that in cell lines transfected with a plas-
mid expressing SETBP1, its ectopic expression leads to increased
full-length SET protein levels. In fact, the overexpression of
SETBP1 might protect SET from protease cleavage and promotes
the formation of a SETBP1/SET/PP2A complex that results in
PP2A inhibition and increased proliferation rate of the leukemic
cells (28). By quantitative RT-PCR, they observed that overexpres-
sion of SETBP1 occurred in 27.6% of patients with AML and
was associated with unfavorable cytogenetic prognostic group,
monosomy 7, and EVI1 overexpression. Similarly to patients
with SETBP1 mutations, overexpression of SETBP1 in AML has
also been associated with significantly shorter overall survival
especially in elderly population (28). Accordingly, increased pY307
PP2A levels were observed in 78.4% of a cohort of patients that
included de novo and secondary AML (53). In approximately two-
third of patients, the PP2A inhibition was attributable to SET
and/or SETBP1 overexpression. However, 34% of the patients with
inactivated PP2A had either FLT3 or NPM1 aberrations, suggest-
ing that PP2A is a secondary rather than a primary event in the
process of leukemogenesis (53). Recently, SET expression studies
in AML cell lines and CD34+ progenitors from healthy individu-
als and AML patients revealed that it was significantly increased in
the cell lines tested as well as in primary patient samples harboring
FLT3-ITD, NRASQ61L, and JAK3A572V genetic lesions (54).
In AML, the coexistence of PP2A-pathway abnormalities with
well-known unfavorable molecular markers may provide novel
explanations for the worse prognosis associated with those cases.
ACUTE LYMPHOBLASTIC LEUKEMIA
Almost 20% of adult patients affected by B-cell ALL harbor the
Philadelphia chromosome translocation Ph1, t(9;22)(q34;q11),
which usually differs from CML cases because the BCR/ABL1
gene product has a molecular weight of 190 kDa (p190) (55).
Although the inclusion of TKIs in the treatment of Ph1+ ALL has
significantly improved the proportion of patient achieving com-
plete remission, it remains an incurable disease with a very dismal
prognosis (56). In Ph1 ALL progenitors, the inhibition of PP2A
activity occurs in a SET-dependent manner and the reactivation
of the PP2A by FTY720 causes growth inhibition and induction
of caspase-dependent apoptosis toward p190 down-regulation
(38). Interestingly, the induction of apoptosis and inhibition of
cytokine-dependent clonogenic potential are observed regardless
of the presence of T315I mutation and without compromising
normal myelopoiesis, stressing the concept that FTY720 could
represent a feasible and effective treatment also in highly resistant
Ph1+ ALL (and CML) cases (38).
T-cell ALL
T-cell ALL (T-ALL) is a malignancy often characterized by aggres-
sive clinical outcome, high relapse risk, and poor prognosis (57).
Recurrent chromosomal aberrations and gene mutations have
been identified, although a consistent proportion of patients lack
molecular or cytogenetic abnormalities (58). By combining array-
CGH (comparative genomic hybridization) and gene expression
profiling (GEP), a recurrent deletion at 9q34 was identified among
patients with T-ALL (59). The del(9)(q34.11q34.13) results in
SET–NUP214 fusion gene that binds in the promoter regions of
the HOXA gene cluster leading to transcriptional activation of
HOXA9 and HOXA10 probably via CRM1 and DOT1L. In this
study, the knock-down of SET–NUP214 by siRNA down regu-
lated the HOXA expression levels with only mild effect on cell
proliferation and apoptosis. Although conceptually SET–NUP214
fusion protein might affect PP2A activity, no evidence has been
revealed in this regard.
Although the paucity of data regarding the involvement of
PP2A or SET in ALL could not draw any conclusive remark, the
presence of the Ph1 chromosome in a cohort of patients with ALL
would allow in the next future to investigate the role of PADs in this
subgroup of patients and to test whether the inclusion of PADs in
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standard treatment schedule may add any advantage in cure rate
and survivals.
B-CHRONIC LYMPHOCYTIC LEUKEMIA AND NON-HODGKIN
LYMPHOMAS
B-chronic lymphocytic leukemia (B-CLL) is the most common
leukemia in the Western world, and is characterized by a highly
heterogeneous clinical course (60). In a selected group of patients
with CLL harboring deletion 11q-, reduced PP2A-Aβ subunit
(PPP2R1B) transcript levels were observed. Likewise, alternative
splicing of PP2A-Aβ transcripts was associated with a reduced
activity of PP2A (61). To further confirmation that PP2A signaling
is involved in lymphoid malignancies, SET was found overex-
pressed in primary CLL cells and B-cell non-Hodgkin lymphoma
(NHL) cell line cells in comparison with normal B-cells (62). In
patients with CLL, elevated SET levels associated differently with
known prognostic factors, e.g., Rai stage, CD38 expression, and
IGVH mutational status. Moreover, in CLL cells, increased levels
of SET correlated significantly with disease severity (shorter time
to treatment and overall survival) (62).
The crucial role of PP2A tumor suppressor in NHL is confirmed
by the promising results that FTY720 has shown in pre-clinical
experiments in mantle cell lymphoma (MCL), an aggressive B-
cell malignancy characterized by t(11;14) translocation and cyclin
D1 expression (39, 63). In MCL cell lines, the FTY720-induced
cytotoxicity occurs independent of caspase activation and is asso-
ciated with downmodulation of cyclin D1 (39, 63), phospho-Akt
(39), and the formation of reactive oxygen species (ROS) (63) and
lysosomal membrane permeabilization (39).
The demonstration that the PP2A pathway is affected either in
myeloid or in lymphoid chronic and acute malignancies under-
scores the importance of this tumor suppressor and widens the
spectrum of malignancies that may potentially be treated by PADs.
PP2A AND miRNA
MiRNAs are small (20–24 nucleotide) non-coding RNAs that tar-
get messenger RNA for degradation or translational repression
and also bind RNA binding protein to control their activity on
mRNAs (64–66). Similarly to coding gene, miRNAs could act as
oncogene or tumor suppressor depending on how their expres-
sion levels associate with cancer (67). Although the contribution
of miRNAs to the leukemic transformation or progression has
been clearly demonstrated by different groups, few studies have
focused on the possible interplay between PP2A pathway and miR-
NAs in hematological malignancies. Mavrakis and collaborators
found that miR-19 is highly expressed in ALL and in aggressive
B-cell lymphoma; in a single patient with T-ALL, they identified
two novel translocations, t(9;14)(q34;q11) and t(13;14)(q32;q11),
involving simultaneously Notch1 and the 17–92 cluster including
miR-19 (68). Using an unbiased shRNA screening approach, they
found eight genes whose knock-down resembles miR-19 effects
in vitro, including BIM and PP2A (Ppp2r5e). Hence, in Notch-
induced T-ALL miR-19 overexpression may repress PP2A and
BIM, thus impairing cell survival and apoptosis (68, 69).
Except for miR-19, only a few data have provided evidence of
the possible role of miRNAs in regulating PP2A activity and mostly
relate to miRNA targeting specific PP2A B subunits (70). MiRNAs
might inhibit PP2A transcription (similarly to miR-19) or reg-
ulate the expression of PP2A inhibitory molecules (e.g., CIP2A
and SET) (71). Moreover, miRNAs can indirectly affect the PP2A
pathway by altering the expression of many proteins that cross-talk
with PP2A.
PP2A-ACTIVATING DRUGS
Genetic (SET shRNA-mediated down-regulation) or pharmaco-
logic restoration (i.e., PADs) of PP2A activity halts malignant cell
survival and proliferation both in vitro and in different animal
models of leukemia.
The first drugs to be tested were forskolin, a diterpene derived
from the roots of Coleus forskohlii, and its derivative 1,9-
dideoxyforskolin, which lacks the adenylate cyclase activity but
retains the ability to inhibit PP2A (44) (Table 2). In CML and in
Ph1+ ALL, forskolin may suppress BCR/ABL1 oncogenic poten-
tial in vitro. Interestingly, the anti-leukemic effects of forskolin was
observed either in IM-sensitive or in -resistant BCR/ABL1+ cell
lines including cell lines harboring the T315I mutation that con-
fers resistance to most TKIs (44). Furthermore, PP2A-activation
results in growth suppression, enhanced apoptosis, restored dif-
ferentiation, impaired clonogenic potential, and decreased leuke-
mogenesis in SCID mice injected with BCR/ABL1+ cells regard-
less of their sensitivity to IM (38, 44). Importantly, forskolin
and 1,9-dideoxyforskolin do not affect CD34+ normal cells, thus
preventing toxic effects on normal hematopoiesis (38).
Although forskolin and 1,9-dideoxyforskolin showed good
safety profile and efficacy in pre-clinical studies, the following
study-drug phases focused on a new non-immunosuppressive
compound, e.g., FTY720 (Fingolimod, Gylenia™), recently
approved for the treatment of multiple sclerosis and for prophy-
laxis of solid organ transplantation rejection (72, 73). After phos-
phorylation by sphingosine kinase 2 (SPHK2), FTY720-P tem-
porary promotes internalization of the sphingosine 1-phosphate
receptor (S1PR1). The downregulation of S1PR1 on the sur-
face of lymphocytes prevents their egress from the thymus or
lymph-nodes to blood stream. However, S1P/S1PR1 signaling
may modulate T-cell trafficking as well as T-helper priming,
Table 2 | PP2A-activating drugs (PADs).
Drugs Mechanism of
action
Phase
study
Hematological
malignancies
Forskolin/1,9-
dideoxyforskolin
PP2A reactivation I CML (included T315I)
Fingolimod
OSU-2S
S-FTY720
SET inhibitor I CML, AML
ALL Ph+ and Ph−
Jak2V617MPN
B-CLL and MCL
OP449 SET inhibitor I B-CLL, NHL, CML, AML
CML, chronic myeloid leukemia; ALL, acute lymphoid leukemia; Jak2V617MPN,
Jak2V617F positive myeloproliferative neoplasia; B-CLL, B-cell chronic lympho-
cytic leukemia; NHL, non-Hodgkin lymphoma; MCL, mantle cell lymphoma; AML,
acute myeloid leukemia.
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probably through the sequestration of T-cells within the anti-
gen encounter sites and the regulation of activation molecule
receptors (74). The high oral bioavailability and the absence of
harmful side effects prompted the experimentation of FTY720
into clinical phases.
The anti-leukemic effect of FTY720 is thought to rely on the
ability to re-activate PP2A and it does not require SPHK2 phos-
phorylation (75). The S1PR1 agonist (FTY720-P) neither induces
PP2A activity nor antagonizes the specific molecular aberrations,
for example, BCR–ABL1 or Jak2 pathways (8, 25). By contrast, the
FTY720 derivatives (e.g., OSU-2S and S-FTY720-regioisomer) do
not bind at the docking site of S1PR1 and do not get SPHK2 phos-
phorylated thereby inactive as immunosuppressive drugs while
they still retain the ability to bind SET and activate PP2A (25, 27,
76). Thus, this second generation FTY720 derivatives will over-
come the possible increased conversion to the inactive FTY20-P
by lymphoid B and T cells expressing SPHK2 thereby prevent-
ing the adverse effects (e.g., lymphopenia or bradycardia), which
have been noted in patients with multiple sclerosis at the time of
FTY720 therapy initiation (72).
So far, the data of FTY720 efficacy in hematological malig-
nancies are drawn from pre-clinical studies, although the drug
has been used in patients with multiple sclerosis. Interestingly,
in bone marrow xenografts, PADs nearly abrogated survival of
leukemic progenitors and dramatically impaired survival and
self-renewal of CML and Ph1+ B-ALL stem and/or progenitor
cells, but not of normal quiescent HSCs, through BCR–ABL1-
independent and PP2A-mediated inhibition of Jak2 and β-catenin
(27, 44). This results in apoptosis of CD34+ progenitors in
patients with TKI-sensitive and -resistant CML and translates
into long-term survival with normal myelopoiesis and absence
of toxic effects in BCR/ABL1-positive leukemic mice (27, 38,
44). These findings could represent a model to selectively tar-
get HSCs reservoir sparing normal stem cells. The depletion
of leukemic and genetically unstable stem cells has several bio-
logical and clinical implications. At first, it would prevent the
onset of Ph1 negative sub-clones, which may eventually expand
and contribute to disease progression or relapse in all types
of Ph+ leukemias (77). Second, PADs seem to selectively acti-
vate PP2A in leukemic HSCs without harmful events on normal
hematopoiesis; this could be the rationale to test the efficacy of
PADs in other stem cell-derived malignancies. At last and most
importantly, the eradication of leukemic HSCs would theoreti-
cally cure patients with CML who may eventually discontinue
TKIs treatment.
Recently, Oaks and collaborators provided evidence of FTY720
efficacy in Jak2-driven hematological malignancies (25). PP2A
is inactive in PV and in Jak2V617F MPN progenitors, and this
occurs in an oncogene dose- and kinase-dependent manner and
it is mediated by PP2A inhibitor SET. In Jak2V617F MPN cells,
the FTY720 non-immunosuppressive derivatives (OSU-2S and
S-FTY720-regioisomer) down-regulate Jak2 through the binding
with SET lysine K209, which finally causes the sequestration and
inactivation of SET (25). Of interest, in SCID mice injected with
BA/F3-Jak2V617F cells, FTY720 long-term treatment is associated
with longer survival and decreased leukemic allelic burden without
any injury on cardiac performance.
In myeloid and lymphoid cell lines, treatment with FTY720
restores Bcl-2 dephosphorylation and apoptosis (78, 79). How-
ever, treatment of primary CLL cell lines with FTY720-induced
down-regulation of Mcl-1 but not Bcl-2 and activation of ERK1/2
dephosphorylation. These findings may be consistent with the
hypothesis that FTY720 apoptosis, in CLL, is Mcl-1 and ERK1/2-
mediated (80). FTY720 induces apoptosis in a time- and dose-
dependent manner in primary MCL tumor cells and MCL cell
lines in vitro. In addition, in MCL cells FTY720 treatment results
in the accumulation of cells in G0–G1 and G2–M phases of the
cell cycle. Most importantly, the in vivo therapeutic activity of
FTY720 was shown in severe combined immunodeficient mice
engrafted with Jeko MCL cell line (63). Interestingly, the rate of
cell death is significantly improved in MCL cell lines treated with
FTY720 and milatuzumab, a fully humanized monoclonal anti-
body (mAb) specific for CD74 that increases following induction
of autophagic–lysosomal pathway by FTY720 (39).
Pharmacologic activation of PP2A by FTY720, but not FTY720-
P (phosphorylated), reduced proliferation, inhibited clonogenic
potential, and induced apoptosis in cells harboring the c-KIT
mutation, that is frequently encountered in myeloid malignan-
cies, especially AML (40). Similarly, in vivo treatment with
FTY720 delayed growth of c-KIT+ mutant cells as confirmed
by shrinkage in spleen size and significantly lower bone marrow
infiltration (40).
OP449 (also called COG449)
OP449 (also called COG449) is a novel, cell penetrating peptide,
which acts through the binding with SET, thus preventing the
formation of the SET–PP2A complexes (10). Interestingly, OP449
determined a reduction in cellular levels of the antiapoptotic Bcl-2
family member Mcl-1, which is overexpressed in CLL cells (62).
In CML and AML cell lines, OP449 in combination with tyro-
sine kinases and chemotherapy produced efficient and selective
inhibition of leukemia cell growth as compared with normal cells,
suggesting that SET inhibitors and TKIs or chemotherapy could
represent a new drug combination to overcome drug resistance
(54). In B-CLL and NHL, OP449 has shown to increase sig-
nificantly the activity of PP2A and to inhibit growth of tumor
xenografts in mice (62).
AAL(S), (2-amino-4-(4-heptyloyphenol)-2-methylbutanol)
AAL(S), (2-amino-4-(4-heptyloyphenol)-2-methylbutanol) is a new
non-phosphorylatable FTY720 analog that has recently shown to
reduce airway hyperreactivity and inflammation in an asthma
mouse model (81). In the next future, new FTY720 analogs may
be tested in leukemic cells or mouse model to assess their efficacy
and tolerability in hematological disorders.
Compounds that are able to target tyrosine kinases along
with drugs that act at the epigenetic modifications occurring in
leukemic cells are emerging as highly effective in numerous hema-
tological malignancies (82). Sorafenib (a new generation FLT3
mutant inhibitors) and vorinostat (a histone deacetylases inhibitor,
HDAC) induce tumor-cell death through the induction of PP2A
activity in C16 dihydroceramide-dependent manner (83). Finally,
the induction of complete differentiation of leukemic cells through
the enhanced expression of PP2A regulatory subunits represents
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a mechanism explaining the efficacy of methylprednisolone in the
treatment of lymphoid malignancies (84).
CONCLUSION
Protein phosphatase 2A is a well-characterized phosphatase that
has been found suppressed in hematological malignancies. Over
the past decades, new evidence of its emerging role as tumor sup-
pressor has been clearly provided. The overexpression or aberrant
expression of PP2A inhibitory molecules, like SET or SETBP1 and
CIP2A, contributes to PP2A loss-of-function. In other cases, PP2A
activity is suppressed by unrestrained oncogene signaling driven by
aberrant kinase activity (e.g., BCR–ABL1, Jak2V617F). Numerous
studies have shown that PP2A loss-of-function predict shorter sur-
vival independently from other prognostic factors in myeloid and
lymphoid malignancies, and disease progression/TKI response in
CML. An interesting finding that has emerged recently is that
suppression of PP2A is crucial for the persistence of leukemic
HSCs in CML. Hence, PP2A re-activating drugs might enable
to selectively target the leukemic HSCs that show innate resis-
tance to TKIs allowing the eradication of the leukemic reservoir
and the risk of disease relapse or progression. FTY720 and its
non-immunosuppressive derivatives offered promising results in
pre-clinical models. Although further studies are warranted to
better understand how PP2A inhibition influences leukemia emer-
gence, maintenance, and/or progression, the data reviewed herein
strongly indicate that clinical trials are now imperative to evaluate
the efficacy of PADs in the treatment of patients with hematologic
malignancies.
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